{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(15)"],"submitter":["Sehgal A"],"pubmed_abstract":["<h4>Abstract</h4>We report final analysis results from the PILOT study of lisocabtagene maraleucel (liso-cel) for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Sixty-one adults with R/R LBCL who had received 1 previous line of therapy and met ≥1 hematopoietic stem cell transplantation (HSCT) not intended criterion. Overall response rate (primary end point) was 80%; 54% achieved complete response. After median on-study follow-up of 18.2 months, median duration of response was 23.3 months (95% confidence interval [CI], 6.2 to not reached [NR]). Median progression-free survival (PFS) was 9.0 months (95% CI, 4.2 to NR), median overall survival (OS) was NR (95% CI, 16.3 to NR), and 18-month PFS and OS rates were 43% (95% CI, 30-55) and 59% (95% CI, 45-70), respectively. "],"journal":["Blood advances"],"pagination":["3694-3705"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12305224"],"repository":["biostudies-literature"],"pubmed_title":["Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study."],"pmcid":["PMC12305224"],"pubmed_authors":["Hoda D","Champion R","Hildebrandt GC","Godwin JE","Solomon SR","Chow VA","Yang Z","Gordon LI","Hamadani M","Gupta NK","Sehgal A","Ghosh N","Ogasawara K","Essell J","Yuan B","Wagner-Johnston ND","Riedell PA","Thorpe J","Reagan PM","Fanning S","Nath R","Licitra E"],"additional_accession":[]},"is_claimable":false,"name":"Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study.","description":"<h4>Abstract</h4>We report final analysis results from the PILOT study of lisocabtagene maraleucel (liso-cel) for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Sixty-one adults with R/R LBCL who had received 1 previous line of therapy and met ≥1 hematopoietic stem cell transplantation (HSCT) not intended criterion. Overall response rate (primary end point) was 80%; 54% achieved complete response. After median on-study follow-up of 18.2 months, median duration of response was 23.3 months (95% confidence interval [CI], 6.2 to not reached [NR]). Median progression-free survival (PFS) was 9.0 months (95% CI, 4.2 to NR), median overall survival (OS) was NR (95% CI, 16.3 to NR), and 18-month PFS and OS rates were 43% (95% CI, 30-55) and 59% (95% CI, 45-70), respectively. ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-03-16T09:10:52.435Z","creation":"2025-08-15T03:06:52.668Z"},"accession":"S-EPMC12305224","cross_references":{"pubmed":["40305658"],"doi":["10.1182/bloodadvances.2024015262"]}}